Organization Overview
Historical Acquisition Tree
Alternative names
Key: HonorHealth Research Institute (2) Acquired (2)
Key: HonorHealth Research Institute (26) Acquired (2)
acetylcysteine (mucomyst) (1 trial)
acetylsalicylic acid (aspirin) (1 trial)
atezolizumab (Tecentriq) (1 trial)
cisplatin (platinol) (7 trials)
disulfiram (antabuse) (1 trial)
fluorouracil (efudex) (2 trials)
hydroxychloroquine (plaquenil) (1 trial)
Key: HonorHealth Research Institute (8) Acquired (3)
Adenocarcinoma (Phase 2)
Atherosclerosis (Phase 2)
Brain Injuries (Phase 2)
Brain Injuries, Traumatic (Phase 2)
Carcinoma, Endometrioid (Phase 1)
Carcinoma, Non-Small-Cell Lung (Phase 2)
Carcinoma, Renal Cell (Phase 3)
Coronary Artery Disease (Phase 2)
Coronavirus Infections (Phase 2)
Endometrial Neoplasms (Phase 1)
Intestinal Neoplasms (Phase 1)
Kidney Neoplasms (Phase 3)
Leukemia (Phase 1)
Lung Neoplasms (Phase 2)
Lymphoma (Phase 1)
Multiple Myeloma (Phase 1)
Myelodysplastic Syndromes (Phase 1)
Myeloproliferative Disorders (Phase 1)
Neoplasms (Phase 2)
Neoplasms, Plasma Cell (Phase 1)
Pancreatic Neoplasms (Phase 2)
Precancerous Conditions (Phase 1)
Preleukemia (Phase 1)
Squamous Cell Carcinoma of Head and Neck (Phase 2)
Syndrome (Phase 1)